ArticleOncology reports2019
MicroRNA‑154 functions as a tumor suppressor in bladder cancer by directly targeting ATG7.
Article in Oncology reports, 2019. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 22 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
22 citing papers in PubMed, 35 citations in OpenAlex.
- The emerging roles of miRNA-mediated autophagy in ovarian cancer.Cell death & disease · 2024Review
- Insights on E1-like enzyme ATG7: functional regulation and relationships with aging-related diseases.Communications biology · 2024Review
- Article
- Blood-Based Diagnosis and Risk Stratification of Patients with Pancreatic Intraductal Papillary Mucinous Neoplasm (IPMN).Clinical cancer research : an official journal of the American Association for Cancer Research · 2023Article
- Disorientation effects, circulating small ribonucleic acid, and genetic susceptibility on static postural stability.Heliyon · 2023Article
- Review
- Autophagy inhibition by TSSC4 (tumor suppressing subtransferable candidate 4) contributes to sustainable cancer cell growth.Autophagy · 2022Article
- Non-coding RNA and autophagy: Finding novel ways to improve the diagnostic management of bladder cancer.Frontiers in genetics · 2022Review
- Semaglutide Protects against 6-OHDA Toxicity by Enhancing Autophagy and Inhibiting Oxidative Stress.Parkinson's disease · 2022Article
- Contrast effects of autophagy in the treatment of bladder cancer.Experimental biology and medicine (Maywood, N.J.) · 2021Review
- The Regulating Effect of Autophagy-Related MiRNAs in Kidney, Bladder, and Prostate Cancer.Journal of oncology · 2021Review
- An Autophagy-Related Gene-Based Prognostic Risk Signature for Hepatocellular Carcinoma: Construction and Validation.Computational and mathematical methods in medicine · 2021Article
- Emerging Biomarkers for Predicting Bladder Cancer Lymph Node Metastasis.Frontiers in oncology · 2021Review
- MicroRNAs and target molecules in bladder cancer.Medical oncology (Northwood, London, England) · 2020Review
- Interference with circBC048201 inhibits the proliferation, migration, and invasion of bladder cancer cells through the miR-1184/ITGA3 axis.Molecular and cellular biochemistry · 2020Article
- Autophagy-related gene 7 deficiency caused by miR-154-5p overexpression suppresses the cell viability and tumorigenesis of retinoblastoma by increasing cell apoptosis.Annals of translational medicine · 2020Article
- Article
- MiR-4644 is upregulated in plasma exosomes of bladder cancer patients and promotes bladder cancer progression by targeting UBIAD1.American journal of translational research · 2020Article
- MicroRNA-154: A Novel Candidate for Diagnosis and Therapy of Human Cancers.OncoTargets and therapy · 2020Review
- The Exploitation of Liposomes in the Inhibition of Autophagy to Defeat Drug Resistance.Frontiers in pharmacology · 2020Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
9 authors at 3 institutions in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Aberrant expression of miR‑154 is usually found in cancer studies; however, the role of miR‑154 has seldom been reported in bladder cancer (BCa). In this study, we observed that miR‑154 expression was significantly downregulated in BCa tissues and cell lines, and was associated with several clinicopathological characteristics, including advanced T stage, lymphatic invasion, and distant metastasis. Low expression level of miR‑154 was associated with poor survival outcomes in BCa patients. Overexpression of miR‑154 led to significant decrease in the proliferation, migration, and invasion of BCa cells, while knockdown of miR‑154 yielded the opposite effect. ATG7 was identified as a direct target of miR‑154. ATG7 expression was negatively correlated with miR‑154 expression in BCa tissues. Silencing of ATG7 achieved a similar effect to miR‑154 overexpression; overexpression of ATG7 reversed the inhibitory effect of miR‑154 on BCa cell proliferation, migration and invasion. A xenograft study revealed that miR‑154 inhibited BCa cell growth in vivo, and suppressed ATG7 expression. Altogether, this study demonstrated that miR‑154 may function as a tumor suppressor in BCa and indicated that miR‑154 may be a potential therapeutic target for BCa patients.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.